SF 248

as introduced - 92nd Legislature (2021 - 2022) Posted on 03/26/2021 09:35am

A bill for an act
relating to health; requesting the Board of Regents of the University of Minnesota
establish a pharmacogenomics (PGx) task force; requiring a report; appropriating
money.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:

Section 1. new text begin PHARMACOGENOMICS (PGX) TASK FORCE.
new text end

new text begin Subdivision 1. new text end

new text begin Establishment. new text end

new text begin The University of Minnesota is requested to establish a
pharmacogenomics (PGx) task force to evaluate and assess the current availability of
pharmacogenomics statewide and to develop recommendations for making
pharmacogenomics available statewide. For purposes of this section, "pharmacogenomics"
means the determination of how variation in an individual's genomic information influences
whether a medication and dose is most suitable for that patient.
new text end

new text begin Subd. 2. new text end

new text begin Membership. new text end

new text begin (a) The PGx task force may consist of public members appointed
by the Board of Regents or a designee according to paragraph (c) and four members of the
legislature appointed according to paragraph (e).
new text end

new text begin (b) The Board of Regents shall appoint a chair and the members of the PGx task force
shall elect a co-chair and other officers as the members deem necessary.
new text end

new text begin (c) The Board of Regents or a designee is requested to appoint the following public
members:
new text end

new text begin (1) at least two pharmacists with expertise in pharmacogenomics from the state;
new text end

new text begin (2) at least two physicians licensed and practicing in the state;
new text end

new text begin (3) at least two health system or clinic administrators, or their designees, from the state;
new text end

new text begin (4) a representative of a patient organization that operates in the state;
new text end

new text begin (5) a patient or caregiver with an interest in pharmacogenomics;
new text end

new text begin (6) a patient, caregiver, or provider who is a member of a diverse and underrepresented
community;
new text end

new text begin (7) a representative of the biotechnology industry;
new text end

new text begin (8) a representative of payers, health plans, or insurers;
new text end

new text begin (9) an expert in health informatics;
new text end

new text begin (10) an expert in data management and security;
new text end

new text begin (11) an expert in ethical, legal, and social implications of genomics;
new text end

new text begin (12) an expert in regulatory affairs from the state; and
new text end

new text begin (13) a genetic counselor.
new text end

new text begin (d) Members appointed according to paragraph (c) shall reflect an equitable statewide
geographical representation and representation from diverse groups within the state.
new text end

new text begin (e) The PGx task force shall include two members of the senate, one appointed by the
majority leader and one appointed by the minority leader, and two members of the house
of representatives, one appointed by the speaker of the house and one appointed by the
minority leader.
new text end

new text begin (f) The commissioner of health or a designee shall serve as an ex officio, nonvoting
member of the PGx task force.
new text end

new text begin (g) Initial appointments to the PGx task force shall be made no later than September 1,
2020. Members appointed according to paragraph (c) shall serve for a term of one year.
new text end

new text begin Subd. 3. new text end

new text begin Meetings. new text end

new text begin The Board of Regents or a designee is requested to convene the first
meeting of the PGx task force no later than October 1, 2021. The PGx task force shall meet
at the call of the chairperson or at the request of a majority of PGx task force members.
new text end

new text begin Subd. 4. new text end

new text begin Duties. new text end

new text begin The PGx task force's duties may include, but are not limited to:
new text end

new text begin (1) conducting a comprehensive analysis of strategies that could be undertaken to
implement pharmacogenomics across the state;
new text end

new text begin (2) determining what education in pharmacogenomics is needed by the health care
workforce to improve effectiveness of and reduce adverse reactions to medications through
the use of pharmacogenomics;
new text end

new text begin (3) soliciting input from the public on readiness for adoption of pharmacogenomics;
new text end

new text begin (4) considering the needs and perspectives of diverse and underrepresented communities;
and
new text end

new text begin (5) developing recommendations for:
new text end

new text begin (i) diffusion of pharmacogenomics services into practice across the state;
new text end

new text begin (ii) necessary education;
new text end

new text begin (iii) evaluation of the benefits and value to health of pharmacogenomics; and
new text end

new text begin (iv) building capacity for research on pharmacogenomics needs and capabilities across
the state.
new text end

new text begin Subd. 5. new text end

new text begin Conflict of interest. new text end

new text begin PGx task force members are subject to the Board of Regents
policy on conflicts of interest.
new text end

new text begin Subd. 6. new text end

new text begin Report required. new text end

new text begin By June 30, 2022, the PGx task force shall report to the
chairs and ranking minority members of the legislative committees with jurisdiction over
higher education and health care policy on the activities of the PGx task force under
subdivision 4 and any other issues the PGx task force may choose to report on. At a
minimum, the report must include:
new text end

new text begin (1) a description of the PGx task force's goals; and
new text end

new text begin (2) a description of the outcomes the PGx task force achieved.
new text end

new text begin Subd. 7. new text end

new text begin Expiration. new text end

new text begin The PGx task force expires June 30, 2022.
new text end

Sec. 2. new text begin APPROPRIATION.
new text end

new text begin $250,000 in fiscal year 2022 is appropriated from the general fund to the Board of
Regents of the University of Minnesota for the pharmacogenomics (PGx) task force under
section 1. This is a onetime appropriation. This appropriation is available until expended.
new text end